Optimizing Stroke Prevention after AtriClip Left Atrial Appendage Occlusion: A Narrative Review of Anticoagulation Dilemmas and Imaging Needs

Background: Atrial fibrillation (AF) is a major risk factor for ischemic stroke, with the left atrial appendage (LAA) being the predominant source of thrombi. Surgical LAA occlusion (LAAO) with devices like the AtriClip offers a mechanical alternative to long-term oral anticoagulation (OAC), particularly for patients at high bleeding risk or with OAC contraindications. Purpose: Despite the increasing use of surgical LAAO, optimal post-procedural management—specifically regarding the necessity and duration of anticoagulation and the role of surveillance imaging—remains a subject of debate and practice variability. This comprehensive review examines current anticoagulation strategies, risk stratification tools (CHA2DS2-VASc, HAS-BLED), the efficacy and challenges associated with AtriClip LAAO, and the critical role of postoperative imaging modalities (transesophageal echocardiography [TEE] and cardiac computed tomography angiography [CTA]). Findings: Current guidelines offer divergent recommendations on anticoagulation following surgical LAAO. While LAAO significantly reduces thromboembolic risk, a residual risk persists due to potential incomplete LAA exclusion, thrombus formation on remnant stumps, or non-LAA embolic sources. The CHA2DS2-VASc score remains crucial for risk assessment guiding anticoagulation decisions. Postoperative imaging is vital for confirming complete LAA occlusion, detecting device-related thrombus or residual leaks, and guiding individualized antithrombotic therapy. However, robust long-term data on thromboembolic events post-AtriClip and direct comparisons with contemporary DOAC therapy are limited. Conclusion: Management following surgical LAAO with AtriClip requires a personalized approach, integrating baseline thromboembolic and bleeding risks with imaging-confirmed procedural success. Routine postoperative imaging is essential. Further research, including randomized controlled trials, is needed to standardize post-LAAO anticoagulation protocols, define optimal imaging surveillance strategies, and clarify the management of incomplete LAA occlusion to improve long-term outcomes in AF patients.